The BIO X6™ bioprinter has been awarded the coveted iF gold award for its innovative and cutting-edge design, a feat achieved by less than 1 percent of entries. CELLINK took home two additional design awards for the UP.SIGHT™ single cell dispenser and C.WASH™ plate washing system. This year’s achievements place CELLINK among the top 10 winners in the health/medical category between 2017-2021.

“These awards are a testament to the hours of hard work, dedication to our customers and passion the design team exhibits. It is truly an honor to be recognized for this work and to share it with the talented design team at CELLINK. We are incredibly proud of the BIO X6 in particular given that it has won both the Red Dot award and now the iF gold award, demonstrating the outstanding design quality of the system. We eagerly look forward to seeing what your customers are able to achieve with this system,” says Markus Grip, Global Head of Design, CELLINK.

iF Jury statement about the BIO X6
“Highly professional, non-obtrusive and focused perfectly on the user’s needs: this bioprinter speeds up drug development
tissue engineering. The result is less animal testing, improved novel drug testing and lower costs. Six movable printheads
guarantee major flexibility. A remarkable innovation!”

About the BIO X6™
With six printheads in total for unparalleled versatility, this innovative 3D bioprinter makes it easier to produce more complex and sophisticated constructs with a broader range of materials, cells and crosslinking tools. With six printhead slots and unparalleled flexibility in its configuration, the BIO X6 allows researchers to significantly increase throughput, cut down on print time and improve experiment efficiency. The BIO X6 is the preferred system for researchers seeking to enhance 3D cell culturing, tissue engineering, disease modelling and drug screening applications. View the winning entry in the iF World Design Guide. Learn more about the BIO X6.

A top international, independent group of 98 design experts judged 9,509 entries from about 3,693 participants from 52 nations. For three days, all entries were evaluated, discussed, and scored online using the new iF digital jury tool.

For more information, please contact:
Isabelle Ljunggren, Head of Communications, CELLINK
Phone: +46 708-30 08 90

The information was submitted for publication, through the agency of the contact person set out above on April 14, 2021 at 15:00 CEST.

Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissue and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,600 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq Stockholm under CLNK B.